PDF herunterladen
Synlett 2024; 35(06): 703-705
DOI: 10.1055/a-2213-2408
cluster
Special Issue to Celebrate the Centenary Year of Prof. Har Gobind Khorana

Synthesis of 2′-Deoxy-2′-β-fluoro-4′-azido-5-fluorouridine as a Potential Anti-HIV Agent

Jiao Hou
a   Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou, 450001, P. R. of China
,
Jian-Hua Wang
b   Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Henan Normal University, Xinxiang, 453007, P. R. of China
,
Wenquan Yu  ∗
a   Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou, 450001, P. R. of China
,
Junbiao Chang∗
a   Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou, 450001, P. R. of China
b   Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Henan Normal University, Xinxiang, 453007, P. R. of China
› InstitutsangabenWe thank the Henan Province Epidemic Prevention and Control Emergency Research Project (No. 221111311400), the National Natural Science Foundation of China (Nos. 82130103 and 81773570), and the Young Backbone Teachers Fund of Henan Province (No. 2021GGJS012) for financial support.
› Weitere Informationen
    Lizenzen und Reprints Alle Artikel dieser Rubrik


Abstract

2′-Deoxy-2′-β-fluoro-4′-azido-5-fluorouridine, a new pyrimidine nucleoside analogue of azvudine (FNC), was designed and synthesized. The synthesis of this nucleoside analogue was achieved by bromination of 1,3,5-O-tribenzoyl-2-deoxy-2-fluoro-d-arabinofuranoside, followed by reaction with silylated 5-fluorouracil and further modifications of the sugar moiety, in a 7.6% overall yield over nine steps. The product exhibited good antiviral activity against HIV-1 infection in HEK293T cells.

Key words

deoxyfluoroazidofluorouridine - nucleoside analogues - medicinal chemistry - anti-HIV-1 activity

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/a-2213-2408.
  • Supporting Information


Publikationsverlauf

Eingereicht: 29. Juli 2023

Angenommen nach Revision: 17. November 2023

Accepted Manuscript online:
17. November 2023

Artikel online veröffentlicht:
21. Dezember 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

    • 1a Meng W.-D, Qing F.-L. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2006; 6: 1499
      CrossrefPubMed
    • 1b Jordheim LP, Durantel D, Zoulim F, Dumontet C. Nat. Rev. Drug Discovery 2013; 12: 447
      CrossrefPubMed
    • 1c Cavaliere A, Probst KC, Westwell AD, Slusarczyk M. Future Med. Chem. 2017; 9: 1809
      CrossrefPubMed
    • 1d Guinan M, Benckendorff C, Smith M, Miller GJ. Molecules 2020; 25: 2050
      CrossrefPubMed
    • 1e Geraghty RJ, Aliota MT, Bonnac LF. Viruses 2021; 13: 667
      CrossrefPubMed
    • 1f Kataev VE, Garifullin BF. Chem. Heterocycl. Compd. 2021; 57: 326
      CrossrefPubMed
    • 2a Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF. Chem. Rev. 2014; 114: 9154
      CrossrefPubMed
    • 2b Meanwell M, Silverman SM, Lehmann J, Adluri B, Wang Y, Cohen R, Campeau L.-C, Britton R. Science 2020; 369: 725
      CrossrefPubMed
    • 2c Davison EK, Petrone DA, Meanwell M, Nodwell MB, Silverman SM, Campeau L.-C, Britton R. Nat. Protoc. 2022; 17: 2008
      CrossrefPubMed
    • 2d Rajapaksha DG, Mondal S, Wang JW, Meanwell MW. Med. Chem. Res. 2023; 32: 1315
      Crossref
    • 2e Shet H, Sahu R, Sanghvi YS, Kapdi AR. Chem. Rec. 2022; 22: e202200066
      CrossrefPubMed
    • 3a Chang J. Acc. Chem. Res. 2022; 55: 565
      CrossrefPubMed
    • 3b Chang J. EP 2177527, 2010
      PubMed
    • 3c Chang J, Bao X, Wang Q, Guo X, Wang W, Qi X. CN 101177442, 2008
      PubMed
    • 3d Chang J, Du J, Jiang J, Li Y. WO 2021169861, 2021
      PubMed
    • 4a Wang Q, Hu W, Wang S, Pan Z, Tao L, Guo X, Qian K, Chen C.-H, Lee K.-H, Chang J. Eur. J. Med. Chem. 2011; 46: 4178
      CrossrefPubMed
    • 4b Wu J, Yu W, Fu L, He W, Wang Y, Chai B, Song C, Chang J. Eur. J. Med. Chem. 2013; 63: 739
      CrossrefPubMed
    • 4c Wang R.-R, Yang Q.-H, Luo R.-H, Peng Y.-M, Dai S.-X, Zhang X.-J, Chen H, Cui X.-Q, Liu Y.-J, Huang J.-F, Chang J.-B, Zheng Y.-T. PLoS One 2014; 9: e105617
      CrossrefPubMed
    • 4d Sun L, Peng Y, Yu W, Zhang Y, Liang L, Song C, Hou J, Qiao Y, Wang Q, Chen J, Wu M, Zhang D, Li E, Han Z, Zhao Q, Jin X, Zhang B, Huang Z, Chai J, Wang J.-H, Chang J. J. Med. Chem. 2020; 63: 8554
      CrossrefPubMed
    • 4e Hou J, Peng Y, Liu B, Zhang Q, Wang J.-H, Yu W, Chang J. J. Med. Chem. 2023; 66: 11282
      CrossrefPubMed
    • 5a Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, Wang H, Cui G, Liu Y, Wang J, Li Q, Zeng Z, Yang S, Pei G, Zhu Y, Song W, Yu W, Song C, Dong L, Hu C, Du J, Chang J. Adv. Sci. (Weinheim, Ger.) 2020; 7: 2001435
    • 5b Yu B, Chang J. Innovation 2022; 3: 100321
      PubMed
    • 6a Yang Q, Kang J, Zheng L, Wang X.-J, Wan N, Wu J, Qiao Y, Niu P, Wang S.-Q, Peng Y, Wang Q, Yu W, Chang J. J. Med. Chem. 2015; 58: 3693
      CrossrefPubMed
    • 6b Lv Z, He W, Tian X, Kang J, Liu Y, Peng Y, Zheng L, Wang Q, Yu W, Chang J. Eur. J. Med. Chem. 2015; 101: 103
      CrossrefPubMed
    • 6c Guo M, Kang J, Hou J, Zhang Q, Yu W, Chang J. Youji Huaxue 2020; 40: 221
    • 7a Yu W, Li E, Lv Z, Liu K, Guo X, Liu Y, Chang J. ACS Med. Chem. Lett. 2017; 8: 682
      CrossrefPubMed
    • 7b Li E, Wang Y, Yu W, Lv Z, Peng Y, Liu B, Li S, Ho W, Wang Q, Li H, Chang J. Eur. J. Med. Chem. 2018; 143: 107
      CrossrefPubMed
    • 8a Álvarez P, Marchal JA, Boulaiz H, Carrillo E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R, Aranega A. Expert Opin. Ther. Pat. 2012; 22: 107
      CrossrefPubMed
    • 8b Carrillo E, Navarro SA, Ramírez A, García M. Á, Griñán-Lisón C, Perán M, Marchal JA. Expert Opin. Ther. Pat. 2015; 25: 1131
      CrossrefPubMed
    • 8c Grem JL. Invest. New Drugs 2000; 18: 299
      CrossrefPubMed
    • 8d Pan X, Wang C, Wang F, Li P, Hu Z, Shan Y, Zhang J. Curr. Med. Chem. 2011; 18: 4538
      CrossrefPubMed
    • 8e Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. Pharmacol. Ther. 2020; 206: 107447
      CrossrefPubMed
  • 9 Maag H, Rydzewski RM, McRoberts MJ, Crawford-Ruth D, Verheyden JP. H, Prisbe EJ. J. Med. Chem. 1992; 35: 1440
    CrossrefPubMed
  • 10 2′-Deoxy-2′-β-fluoro-4′-azido-5-fluorouridine (1) A solution of compound 11 (260 mg, 0.474 mmol) in sat. methanolic NH3 (19 mL) was stirred at rt for 20 h, then concentrated and purified by column chromatography [silica gel, MeOH–EtOAc–PE (1:10:10)] to give a white solid; yield: 79 mg (55%); mp 98–100 °C. 1H NMR (400 MHz, CD3OD): δ = 7.89 (dd, J = 6.7, 1.2 Hz, 1 H), 6.35 (ddd, J = 10.0, 5.4, 1.4 Hz, 1 H), 5.13 (dt, J = 53.7, 5.3 Hz, 1 H), 4.43 (dd, J = 22.4, 5.2 Hz, 1 H), 3.76 (t, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, CD3OD): δ = 157.8 (d, J C–F = 26.4 Hz), 149.1, 140.2 (d, J C–F = 233.6 Hz), 125.0 (dd, J C–F = 35.6, 2.1 Hz), 96.9 (d, J C–F = 8.8 Hz), 94.6 (d, J C–F = 194.0 Hz), 82.2 (d, J C–F = 17.1 Hz), 74.3 (d, J C–F = 24.6 Hz), 61.4. HRMS: m/z [M – H]– calcd for C9H8F2N5O5: 304.0499; found: 304.0500.
  • 11 The synthesis and anti-HBV activity of 5-halopyrimidine nucleoside analogue II (X = Cl, Br, I) have been described in ref. 6c. In view of the potent anti-HBV activity of compounds IIa and IIc, these two 5-halopyrimidine analogues were selected for anti-HIV-1 and cytotoxicity evaluation in comparison with the target nucleoside 1.